Several of these targeted agents have shown efficacy in pediatric cancers, as in the use of ALK inhibitors such as crizotinib in ALK-mutated neuroblastoma (NB) [14] and CDK4/6 inhibitors including Palbociclib in pediatric sarcomas [15]. This evidence concerns the gene ALK and neuroblastoma.